PPAR alpha, agonists

DrugDrug NameDrug Indication
DB05187ElafibranorInvestigated for use/treatment in atherosclerosis and diabetes mellitus type 2.
DB06510MuraglitazarInvestigated for use/treatment in diabetes mellitus type 2.
DB09198LobeglitazoneLobeglitazone was approved by the Ministry of Food and Drug Safety (South Korea) in 2013, and is being monitored by postmarketing surveillance until 2019. Lobeglitazone is not approved for use by either the Food and Drug Administration (USA), Health Canada, or by the European Medicines Agency for use in the management of diabetes.
DB12662NaveglitazarNot Available